NMRA
Neumora Therapeutics, Inc.
0.55$
-7.7%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Cash Flow
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -0.18 | -0.18 | -0.50 | -0.76 | -1.03 | -1.15 | -1.26 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| – | 0.01 | 0.03 | 0.05 | 0.11 | 0.25 | 0.18 | |
| 0.50 | 0.50 | 1.07 | 0.15 | – | – | – | |
| – | -0.02 | -0.01 | -0.05 | -0.06 | 0.14 | 0.00 | |
| 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | |
| -0.07 | -0.07 | -0.01 | -1.11 | 0.41 | -0.44 | 1.03 | |
| – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | – | |
| 0.37 | 0.37 | 0.00 | – | – | 0.00 | 0.35 | |
| 1.51 | 1.51 | 1.93 | 0.76 | 1.46 | 0.14 | 0.47 | |
| 1.26 | 1.26 | 1.43 | -1.10 | 0.84 | -1.45 | 0.24 | |
| – | -0.18 | -0.50 | -0.76 | -1.03 | -1.15 | -1.26 |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.